Snehal Patel, Global Head of Cell Therapy Manufacturing at Bristol Myers Squibb, stand outside the facility on Monday in Bothell. (Andy Bronson / The Herald)

Snehal Patel, Global Head of Cell Therapy Manufacturing at Bristol Myers Squibb, stand outside the facility on Monday in Bothell. (Andy Bronson / The Herald)

Cancer patients nationwide send their blood cells to Bothell

At a Bristol Myers Squibb lab, the cells are altered and returned to patients fighting non-Hodgkin’s lymphoma.

BOTHELL — It might look like an ordinary manufacturing center from the parking lot, but this “factory” is busy producing cancer-fighting cells.

A Bristol Myers Squibb “therapy manufacturing center” in Bothell is ramping up production of a new blood-cancer treatment after it received federal approval earlier this year.

On Feb. 5, the U.S. Food and Drug Administration approved Breyanzi, a cell-based genetic therapy, for commercial use. A one-time infusion, it treats patients with non-Hodgkin’s lymphoma when at least two treatments haven’t worked or have stopped working.

Breyanzi involves re-engineering and revving up a patient’s own immune cells to detect, attack and kill cancer cells.

The 68,000-square-foot Bothell site is equipped to modify T-cells, said Snehal Patel, vice president and global head of cell therapy manufacturing.

Non-Hodgkin’s lymphoma is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. The disorder weakens the immune system and its ability to fight infection. In the U.S., it accounts for about 4% of all cancers. The American Cancer Society estimates that nearly 82,000 people this year will be diagnosed with the non-Hodgkin’s lymphoma.

The personalized therapy begins at one of 40 treatment centers, where a patient’s T-cells, a type of white blood cell, are collected.

The cells are then carefully preserved and shipped to the Bothell site, which serves patients throughout the U.S., Patel said.

At the facility, the cells are genetically altered to locate and destroy cancer cells.

A viral vector — a virus that’s been modified so that it can’t replicate — is used to deliver genetic material to the T-cell. Once it reaches the target, it makes changes to the cell, enabling it to identify and destroy cancer cells. A few weeks later, the enhanced T-cells are returned to the patient in the form of a one-time infusion. Patients are then monitored for several weeks, staying close to the treatment center.

“Breyanzi has deep Pacific Northwest roots from being developed by local scientific teams,” said Ann Lee, senior vice president and head of cell therapy development and operations at Bristol Myers.

Juno Therapeutics, a Bothell biotech firm, began the process in 2013, collaborating with the Fred Hutchinson Cancer Research Center in Seattle, Seattle Children’s Research Institute and Memorial Sloan-Kettering Cancer Center in New York.

Juno was purchased by Celgene Corp in 2018 for $9 billion. A year later, Bristol Myers Squibb acquired Celgene in a $74 billion deal.

The Bristol Meyers Squibb manufacturing center and a separate Canyon Park Business Park location currently employ about 550 people, but the company plans to expand its footprint with the addition of a 44,000-square-foot business center to support employees and enable further manufacturing expansion.

“Travis Lynn and Rian Zeigler — two of our guys — are helping design the new business center,” said Patel, describing it as a “significant investment.”

“We’re proud to invest in the Bothell area,” Patel said “We have employees from Everett, Mill Creek, Monroe and Snohomish. We’ve also recently hired some Boeing folks, giving them the chance to enter the health care space.”

Bristol Myers recently partnered with Shoreline Community College to develop a biotech certification program that prepares students for entry-level laboratory work, Patel said.

Breyanzi is the first of two Bristol Myers cell therapy treatments to receive FDA approval this year for commercial distribution.

In March, the FDA approved Abecma for multiple myeloma, a rare blood cancer that blocks bone marrow from making enough healthy blood cells. The disorder can result in low blood counts that weaken the immune system and damage the bones and kidneys.

Abecma was developed by Celgene and a Boston-based biotech, bluebird bio. It will be produced at a Bristol Myers cell therapy manufacturing site in New Jersey.

Janice Podsada; jpodsada@heraldnet.com; 425-339-3097; Twitter: JanicePods

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Business

A closing sign hangs above the entrance of the Big Lots at Evergreen and Madison on Monday, July 22, 2024, in Everett, Washington. (Ryan Berry / The Herald)
Big Lots announces it will shutter Everett and Lynnwood stores

The Marysville store will remain open for now. The retailer reported declining sales in the first quarter of the year.

George Montemor poses for a photo in front of his office in Lynnwood, Washington on Tuesday, July 30, 2024.  (Annie Barker / The Herald)
Despite high mortgage rates, Snohomish County home market still competitive

Snohomish County homes priced from $550K to $850K are pulling in multiple offers and selling quickly.

Henry M. Jackson High School’s robotic team, Jack in the Bot, shake hands at the 2024 Indiana Robotics Invitational.(Henry M. Jackson High School)
Mill Creek robotics team — Jack in the Bot — wins big

Henry M. Jackson High School students took first place at the Indiana Robotic Invitational for the second year in a row.

The computer science and robotics and artificial intelligence department faculty includes (left to right) faculty department head Allison Obourn; Dean Carey Schroyer; Ishaani Priyadarshini; ROBAI department head Sirine Maalej and Charlene Lugli. PHOTO: Arutyun Sargsyan / Edmonds College.
Edmonds College to offer 2 new four-year degree programs

The college is accepting applications for bachelor programs in computer science as well as robotics and artificial intelligence.

FILE — Boeing 737 MAX8 airplanes on the assembly line at the Boeing plant in Renton, Wash., on March 27, 2019. Boeing said on Wednesday, Feb. 21, 2024, that it was shaking up the leadership in its commercial airplanes unit after a harrowing incident last month during which a piece fell off a 737 Max 9 jet in flight. (Ruth Fremson/The New York Times)
Federal judge rejects Boeing’s guilty plea related to 737 Max crashes

The plea agreement included a fine of up to $487 million and three years of probation.

Neetha Hsu practices a command with Marley, left, and Andie Holsten practices with Oshie, right, during a puppy training class at The Everett Zoom Room in Everett, Washington on Wednesday, July 3, 2024. (Annie Barker / The Herald)
Tricks of the trade: New Everett dog training gym is a people-pleaser

Everett Zoom Room offers training for puppies, dogs and their owners: “We don’t train dogs, we train the people who love them.”

Andy Bronson/ The Herald 

Everett mayor Ray Stephenson looks over the city on Tuesday, Jan. 5, 2015 in Everett, Wa. Stephanson sees  Utah’s “housing first” model – dealing with homelessness first before tackling related issues – is one Everett and Snohomish County should adopt.

Local:issuesStephanson

Shot on: 1/5/16
Economic Alliance taps former Everett mayor as CEO

Ray Stephanson will serve as the interim leader of the Snohomish County group.

Molbak's Garden + Home in Woodinville, Washington will close on Jan. 28. (Photo courtesy of Molbak's)
After tumultuous year, Molbak’s is being demolished in Woodinville

The beloved garden store closed in January. And a fundraising initiative to revitalize the space fell short.

Everett Mayor Cassie Franklin, Advanced Manufacturing Skills Center executive director Larry Cluphf, Boeing Director of manufacturing and safety Cameron Myers, Edmonds College President Amit Singh, U.S. Rep. Rick Larsen, and Snohomish County Executive Dave Somers participate in a ribbon-cutting ceremony on Tuesday, July 2 celebrating the opening of a new fuselage training lab at Paine Field. Credit: Arutyun Sargsyan / Edmonds College
‘Magic happens’: Paine Field aerospace center dedicates new hands-on lab

Last month, Edmonds College officials cut the ribbon on a new training lab — a section of a 12-ton Boeing 767 tanker.

Gov. Jay Inslee presents CEO Fredrik Hellstrom with the Swedish flag during a grand opening ceremony for Sweden-based Echandia on Tuesday, July 30, 2024, in Marysville, Washington. (Ryan Berry / The Herald)
Swedish battery maker opens first U.S. facility in Marysville

Echandia’s marine battery systems power everything from tug boats to passenger and car ferries.

Helion Energy CEO and co-founder David Kirtley talks to Governor Jay Inslee about Trenta, Helion’s 6th fusion prototype, during a tour of their facility on Tuesday, July 9, 2024 in Everett, Washington. (Olivia Vanni / The Herald)
State grants Everett-based Helion a fusion energy license

The permit allows Helion to use radioactive materials to operate the company’s fusion generator.

People walk past the new J.sweets storefront in Alderwood Mall on Thursday, July 25, 2024, in Lynnwood, Washington. (Olivia Vanni / The Herald)
New Japanese-style sweets shop to open in Lynnwood

J. Sweets, offering traditional Japanese and western style treats opens, could open by early August at the Alderwood mall.

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.